Health Discovery (HDVY) 10-K/A 14 May 20 2019 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	May 12, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTH DISCOVERY CORP
Entity Central Index Key	0001141788
Document Type	10-K/A
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 19,020,329
Entity Common Stock, Shares Outstanding		388,646,386
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash	$ 2,295,720	$ 67	$ 43,543	$ 41,251
Investment in Available For Sale Securities (Note L)				154,374
Legal fee retainer	16,796
Total Current Assets	2,312,516	67	43,543	195,625
Patents, Less Accumulated Amortization of $3,985,794, $3,832,887, $3,570,167 and $3,307,448 as of December 31, 2019, 2018, 2017 and 2016 respectively		152,908	415,627	678,346
Total Assets	2,312,516	152,975	459,170	873,971
Current Liabilities
Accounts Payable	21,483	148,208	152,648	39,823
Accrued Wages	440,089	339,677	147,500
Dividends Payable	206,637	206,637	206,637	206,637
Accrued Interest	16,688	27,064	1,210
Deferred Revenue		18,077	43,388	43,388
Common Stock Warrants Liability	1,898,126
Convertible Debt	200,000	407,060
Total Current Liabilities	2,783,023	1,146,723	551,383	289,848
Long Term Liabilities
Deferred Revenue			18,077	61,465
Convertible Debt			175,000
Total Liabilities	2,783,023	1,146,723	744,460	351,313
Stockholders' Equity
Preferred Stock, Convertible, 45,000,000 Shares Authorized; No Par Value, 0 Issued and Outstanding December 31, 2019; 30,000,000 issued and outstanding December 31, 2018, 2017 and 2016		900,000	900,000	900,000
Common Stock, No Par Value, 450,000,000 Shares Authorized;388,648,386 Shares Issued and Outstanding December 31, 2019;268,718,989 Shares Issued and Outstanding December 31, 2018, 2017 and 2016	28,909,761	29,047,226	28,960,210	28,894,271
Accumulated Deficit	(29,380,268)	(30,940,974)	(30,145,500)	(29,271,613)
Total Stockholders' Equity (Deficit)	(470,507)	(993,748)	(285,290)	522,658
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,312,516	$ 152,975	$ 459,170	$ 873,971

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Balance Sheets
Patents, accumulated amortization	$ 3,985,794	$ 3,832,887	$ 3,570,167	$ 3,307,448
Preferred stock, par value (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Preferred stock, shares outstanding	0
Common stock, par value (in dollars per share)	$ 0
Common stock, shares authorized	450,000,000	450,000,000	450,000,000	450,000,000
Common stock, shares issued		388,648,386
Common stock, shares outstanding		268,718,989	268,718,989	268,718,989

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total Revenue	$ 1,518,806	$ 44,300	$ 44,951	$ 43,512
Depreciation and Amortization	152,908	262,719	262,719	262,914
Professional and Consulting Fees	83,735	59,456	126,799	213,977
Legal Fees	86,997	10,359	72,020	32,458
Research and Development Fees	0	0	0	27,000
Compensation	371,690	285,421	308,631	282,195
Other General and Administrative Expenses	745,023	195,965	134,382	179,093
Total Operating Expenses	1,440,353	813,920	904,551	997,657
Income (Loss) From Operations	78,453	(769,620)	(859,600)	(954,145)
Proceeds from Arbitration	5,161,035
Interest Income	721
Arbitration related fee	(3,642,170)
Interest Expense	(37,333)	(25,854)	(1,210)
Change in Fair Value of Warrants Liability				(1,196,612)
Unrealized Gain on Available for Sale Securities (Note L)				12,395
Realized Loss on Available for Sale Securities (Note L)			(13,077)
Gain on Payables Restructuring				69,743
Total Other Income (Expense)	1,482,253	(25,854)	(14,287)	(1,114,474)
Net Income (Loss)	1,560,706	(795,474)	(873,887)	(2,068,619)
Income (Loss) Attributable to Common Stockholders	$ 1,560,706	$ (795,474)	$ (873,887)	$ (2,068,619)
Weighted Average Outstanding Shares	388,646,386	271,718,989	271,718,989	271,718,989
(Loss) Income Per Share Attributable to Common Stockholders	$ 0	$ 0	$ 0	$ 0
Licensing and Development
Total Revenue	$ 18,806	$ 44,300	$ 44,951	$ 43,512
Licensing Revenue from Arbitration
Total Revenue	$ 1,500,000

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock	Common StockShare-based Payment Arrangement, Employee	Common StockShare-based Payment Arrangement, Nonemployee	Common Stock	Accumulated Deficit	Share-based Payment Arrangement, Employee	Share-based Payment Arrangement, Nonemployee	Total
Balance at beginning of period at Dec. 31, 2015	$ 560,732			$ 27,410,930	$ (27,202,994)			$ 768,668
Balance at beginning of period (in shares) at Dec. 31, 2015	30,000,000			268,718,989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based Compensation Expense		$ 108,311	$ 88,418			$ 108,311	$ 88,418
Common Stock Warrants Liability	$ 339,268			$ 1,196,612				1,535,880
Common Stock Issued				$ 90,000				90,000
Common Stock Issued (in shares)				3,000,000
Net Income (Loss)					(2,068,619)			(2,068,619)
Balance at ending of period at Dec. 31, 2016	$ 900,000			$ 28,894,271	(29,271,613)			522,658
Balance at ending of period (in shares) at Dec. 31, 2016	30,000,000			271,718,989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based Compensation Expense		19,201	46,738			19,201	46,738
Net Income (Loss)					(873,887)			(873,887)
Balance at ending of period at Dec. 31, 2017	$ 900,000			$ 28,960,210	(30,145,500)			(285,290)
Balance at ending of period (in shares) at Dec. 31, 2017	30,000,000			271,718,989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)								(188,567)
Balance at ending of period at Mar. 31, 2018								(452,825)
Balance at beginning of period at Dec. 31, 2017	$ 900,000			$ 28,960,210	(30,145,500)			(285,290)
Balance at beginning of period (in shares) at Dec. 31, 2017	30,000,000			271,718,989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based Compensation Expense		$ 3,200	83,816			$ 3,200	83,816
Net Income (Loss)					(795,474)			(795,474)
Balance at ending of period at Dec. 31, 2018	$ 900,000			$ 29,047,226	(30,940,974)			(993,748)
Balance at ending of period (in shares) at Dec. 31, 2018	30,000,000			271,718,989
Balance at beginning of period at Mar. 31, 2018								(452,825)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)								(191,738)
Balance at ending of period at Jun. 30, 2018								(631,912)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)								(202,656)
Balance at ending of period at Sep. 30, 2018								(803,228)
Balance at beginning of period at Dec. 31, 2018	$ 900,000			$ 29,047,226	(30,940,974)			(993,748)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)								(176,879)
Balance at ending of period at Mar. 31, 2019								(1,167,320)
Balance at beginning of period at Dec. 31, 2018	$ 900,000			$ 29,047,226	(30,940,974)			(993,748)
Balance at beginning of period (in shares) at Dec. 31, 2018	30,000,000			271,718,989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based Compensation Expense			$ 512,952				$ 512,952
Common Stock Warrants Liability				$ 1,196,612,000
Series C Preferred Stock Converted to Common Stock	$ (900,000)			$ 900,000
Series C Preferred Stock Converted to Common Stock (In shares)	(30,000,000)			30,000,000
$300,000 Convertible Debt Converted to Common				$ 347,709				$ 347,709
$300,000 Convertible Debt Converted to Common (In shares)				86,927,397				86,927,397
Reclassification of Common Stock Warrants				$ (1,898,126)				$ (1,898,126)
Net Income (Loss)					1,560,706			1,560,706
Balance at ending of period at Dec. 31, 2019				$ 28,909,761	$ (29,380,268)			(470,507)
Balance at ending of period (in shares) at Dec. 31, 2019				388,646,386
Balance at beginning of period at Mar. 31, 2019								(1,167,320)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)								2,124,498
Balance at ending of period at Jun. 30, 2019								1,466,822
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)								(236,395)
Balance at ending of period at Sep. 30, 2019								$ 1,230,427

Statements of Changes in Stoc_2

Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	Dec. 31, 2019	Apr. 22, 2019
Convertible promissory note
Amount of debt	$ 300,000	$ 200,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash Flows From Operating Activities
Net Income (Loss)	$ (176,879)	$ (188,567)	$ 1,560,706	$ (795,474)	$ (873,887)	$ (2,068,619)
Adjustments to Reconcile Net Income (Loss) to Net Cash Used in Operating Activities:
Stock-based Compensation for Employees				3,200	19,201	108,311
Stock-based Compensation for Directors and Consultants			512,952	83,816	46,738	88,418
Gain on Payables Restructuring						(69,743)
Realized Loss on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note L)					13,077
Unrealized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note L)						(12,395)
Increase in Warrants Liability						1,196,612
Depreciation and Amortization	65,680	65,680	152,908	262,719	262,719	262,914
(Increase) Decrease in Accounts Payable			(126,725)	(4,440)	112,825	71,933
Increase in Accrued Wages			100,412	192,177	147,500
Accrued Interest			37,333	25,854	1,210
(Decrease) in Deferred Revenue			(18,077)	(43,388)	(43,388)	(43,388)
Increase in Legal Fee Retainer			(16,796)
Net Cash Provided by (Used in) Operating Activity			2,202,713	(275,536)	(314,005)	(465,957)
Cash Flows From Investing Activities:
Proceeds from Sale of Available for Sale Securities (Note L)					141,297
Net Cash Provided by Investing Activity					141,297
Cash Flows From Financing Activities:
Proceeds from Common Stock Issuance						90,000
Proceeds from Short Term Notes			122,000
Proceeds from Convertible Debt			92,940	232,060	175,000
Repayment of Short Term Notes			(122,000)
Net Cash Provided by Financing Activity			92,940	232,060	175,000	90,000
Net Increase (Decrease) in Cash			2,295,652	(43,476)	2,292	(375,957)
Cash, at Beginning of Year	$ 67	$ 43,543	67	43,543	41,251	417,208
Cash, at End of Year			2,295,720	$ 67	$ 43,543	41,251
Non-cash Financing and Investing Activities
Series C Preferred Stock Issuance						$ 339,268,000
Conversion of Series C Preferred Stock to Common Stock			900,000,000
Conversion of debt to Common Stock			347,709,000
Reclassification of Common Stock Warrants Liability			$ 1,898,126,000

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES DESCRIPTION OF BUSINESS Health Discovery Corporation (“HDC” or the “Company”) is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery. The terms artificial intelligence and machine learning are sometimes used to describe pattern recognition tools. HDC’s mission is to use its patents, intellectual prowess, and clinical partnerships principally to identify patterns that can advance the science of medicine, as well as to advance the effective use of our technology in other diverse business disciplines, including the high-tech, financial, and healthcare technology markets. Our historical foundation lies in the molecular diagnostics field where we have made a number of discoveries that may play a role in developing more personalized approaches to the diagnosis and treatment of certain diseases. However, our Support Vector Machines (“SVM”) assets in particular have broad applicability in many other fields. Intelligently applied, HDC’s pattern recognition technology can be a portal between enormous amounts of otherwise undecipherable data and truly meaningful discovery. Our Company’s principal asset is its intellectual property, which includes advanced mathematical algorithms called SVM, as well as biomarkers that we discovered by applying our SVM techniques to complex genetic and proteomic data. Biomarkers are biological indicators or genetic expression signatures of certain disease states. Our intellectual property is protected by 31 patents that have been issued or are currently pending around the world. Our business model has evolved over time to respond to business trends that intersect with our technological expertise and our capacity to professionally manage these opportunities. In the beginning, we sought only to use our SVMs internally in order to discover and license our biomarker signatures to various diagnostic and pharmaceutical companies. Today, our commercialization efforts include: utilization of our discoveries and knowledge to help develop diagnostic and prognostic predictive tests; licensing of the SVM technologies directly to diagnostic companies; and, the potential formation of new ventures with domain experts in other fields where our pattern recognition technology holds commercial promise. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Accordingly, actual results could differ from those estimates. Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the patent impairment. REVENUE RECOGNITION Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements. These arrangements are generally governed by contracts that dictate responsibilities and payment terms. The Company recognizes revenues as they are earned over the duration of a license agreement once all contractual obligations have been fulfilled. If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. CASH Cash includes cash deposited with financial institutions. PATENTS Initial costs paid to purchase patents are capitalized and amortized using the straight-line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2019, the Company does not believe there has been any impairment of its patents. The Company has analyzed the respective carrying value of our patent portfolio at December 31, 2016, 2017, 2018 and 2019 and has concluded that the portfolio was not impaired during this period. INVESTMENTS The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies. COMMON STOCK WARRANT LIABILITY In the event the number of shares or warrants of Common Stock granted exceeds the number of shares available if the holders exercised all of the previously issued outstanding options and warrants, the Company accounts for this excess as a Common Stock Warrant Liability, which is adjusted to fair value at the end of each reporting period. If and when the Company authorizes sufficient shares of common stock and preferred stock, the Common Stock Warrant Liability is reclassified to equity at the fair value of the liability at the date of reclassification. INCOME TAXES The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled. In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation is made of the probability of being able to realize the future benefits indicated by such assets. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies. STOCK-BASED COMPENSATION Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model. Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates. Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule. Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award. RESEARCH AND DEVELOPMENT EXPENSE The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. The research and development costs were $0 for 2019, 2018 and 2017 and $27,000 in 2016. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company’s financial instruments consist of cash, available for sale securities, and accounts payable. The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note L for discussion regarding the valuation of the Company’s investment in available for sale securities. NET INCOME (LOSS) PER SHARE Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss for the years ended December 31, 2018, 2017 and 2016, the calculation of diluted per share amounts would create an anti-dilutive result and therefore are not presented in the following table. Potentially dilutive shares at December 31, 2019, 2018, 2017 and 2016 include options and warrants outstanding of 116,375,000, 108,375,000, 106,125,000 and 97,375,000 respectively. The following is an analysis of the basic and diluted earnings per common share computations for the year ended December 31, 2019: Year ended December 31, 2019 Basic: Net income attributable to common stockholders $ 1,560,706 Basic weighted average common shares outstanding 388,646,386 Net income per share attributable to common stockholders - basic $ Diluted: Net income attributable to common stockholders $ 1,560,706 Basic weighted average common shares outstanding 345,742,711 Effect of dilutive securities: Conversion of options and warrants 86,927,397 Conversion of preferred shares to common shares 30,000,000 Diluted weighted average common shares outstanding 462,670,108 Net income per share attributable to common stockholders - diluted $ Please refer to Note L regarding detail for outstanding stock options. CONCENTRATIONS OF CREDIT RISK The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account. From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC. Management believes the risk of loss of cash balances in excess of the insured limit to be low.

ARBITRATION

ARBITRATION	12 Months Ended
	Dec. 31, 2019
ARBITRATION
ARBITRATION	Note B – ARBITRATION In January 2017, the Company notified NeoGenomics Laboratories, Inc. (“NeoGenomics” or “NEO”) of the Company’s election to terminate all licenses that are subject to the Master License Agreement (the “MLA”) dated January 6, 2012, between the Company and NeoGenomics. The MLA was filed with the Securities and Exchange Commission (“SEC”) on January 11, 2012 as an exhibit to a Current Report on Form 8‑K. Subsequently, the Company and NeoGenomics attempted to resolve the matter through alternative dispute resolution, including but not limited to, mediation. While these efforts were unsuccessful, the Company ultimately filed a Demand for Arbitration (“Arbitration”) with the American Arbitration Association’s Panel of Arbitrators (the “Panel” or “Arbitrators”). On April 25, 2019, the Panel issued their ruling (the “Final Award”). Section XXI, the Conclusion of the Final Award, states: Based on the foregoing, the Panel concludes as follows: 1. Effective immediately, the MLA is terminated. 2. The Company is awarded $1,500,000 based on the Panel’s conclusion that SmartFlow infringes a Valid Patent Claim and internal use by NEO is subject to Milestone and Royalty payments. 3. The Company is awarded $5,100,000 based on the Panel’s conclusion that NEO failed to use its best efforts with respect to the development and commercialization of SVM-CYTO. 4. Pursuant to Section 12.2 of the MLA, NEO shall reimburse the Company $8,694. 5. As discussed in this Final Award, all other claims by the Company are hereby denied. 6. NEO’s request for a Declaratory Judgment is denied. 7. All of NEO’s counterclaims are denied. 8. All other claims, counterclaims, defenses, requests for relief, to the extent not specifically addressed in this Final Award are hereby denied. Therefore, the sum award for the Company is $6,608,694 plus interest accrued from date of the Final Award to date of payment. Additionally, the Panel holds that the MLA is terminated with the exception of the obligations expressly stated in Section 8.2. Section 8.2 of the MLA requires NeoGenomics to, among other things; continue its obligations to make payment of any sum due to the Company pursuant to Article 3 of the MLA, License Fees and Royalty Payments. In 2019, the Company received a total payment of $6.6 million as a result of the NeoGenomics arbitration ruling. $1.5 million of the arbitration award was attributed to “milestone and royalty payments”, with the remaining $5.1 million attributed to punitive damages. Hence, the Company reported $1.5 million as revenues and $5.1 million as other income for the year ending December 31, 2019. The company also incurred arbitration related fees of $3,642,170 in 2019. These fees were related to the expense of contingency financing that was required in order to successfully resolve the Arbitration.

DEFERRED REVENUE

DEFERRED REVENUE	12 Months Ended
	Dec. 31, 2019
DEFERRED REVENUE
DEFERRED REVENUE	Note C – DEFERRED REVENUE Deferred revenue represents the unearned portion of payments received in advance for licensing or service agreements. The deferred revenue relates to the Company’s settlement with Vermillion. The entire amount has been amortized over the life of the related patents. The Company had no unearned revenue as of December 31, 2019. Deferred revenue was $18,077 at December 31, 2018, $61,465 at December 31, 2017 and $104,853 at December 31, 2016. The long-term portion of unearned revenue represents the remaining term of the agreements or the remaining lives of the underlying patents, as appropriate, and ranges from one to seven years.

PATENTS

PATENTS	12 Months Ended
	Dec. 31, 2019
PATENTS
PATENTS	Note D – PATENTS The Company has acquired a group of patents related to biotechnology and certain machine learning tools used for diagnostic and drug discovery. The cost and accumulated amortization as of December 31, 2019, 2018, 2017 and 2016 are as follows: 2019 2018 2017 2016 Cost of Patents $ 3,985,794 $ 3,985,794 $ 3,985,794 $ 3,985,794 Accumulated Amortization (3,985,794) (3,832,887) (3,570,167) (3,307,448) Patents, Net of Amortization $ - $ 152,908 $ 415,627 $ 678,346

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2019
INVESTMENTS
INVESTMENTS	Note E – INVESTMENTS On March 27, 2007, the Company and an investment partner formed SVM Capital, LLC (“SVM Capital”) as an equity investment for purposes of utilizing SVM as a quantitative investment management technique. The Company owns 45% of the membership interest but does not have control over the entity. The Company does not have any obligation to fund or provide support to SVM Capital. Accordingly, the investment is accounted for using the equity method of accounting. The Company’s initial investment was $5,000 and the license to use the SVM technology applied to financial markets. The carrying value of this investment was zero as of December 31, 2019, 2018, 2017 and 2016.

COMMON STOCK WARRANTS LIABILITY

COMMON STOCK WARRANTS LIABILITY	12 Months Ended
	Dec. 31, 2019
COMMON STOCK WARRANTS LIABILITY
COMMON STOCK WARRANTS LIABILITY	Note F – COMMON STOCK WARRANTS LIABILITY In September 2015, the Company completed a private placement of 30,000,000 shares of preferred stock as well as a private placement of 4,000,000 shares of common stock and issued warrants to purchase an additional 34,000,000 shares of common stock. Due to the warrant features that accompany the sale of the Company’s preferred and common shares, if all outstanding options and warrants were exercised, the Company would not have sufficient shares of common stock to meet the exercised options and warrants. As a result, these warrants were required to be classified as a liability as of December 31, 2015. The Company increased its authorized shares during the year ending December 31, 2016 and reclassified the liability to stockholders' equity in the amount of $1,196,612 On December 31, 2019, as more fully disclosed in Note I, the Note Holders converted the Promissory Note into 86,927,397 shares of Common Stock, thereby causing the Company to again exceed its authorized number of shares of Common Stock to be issued. Accordingly, the Company reclassified $1,898,126 from stockholders’ equity to common stock warrants liability as of December 31, 2019. The common stock warrants liability is recorded based upon the number of warrants which exceed the number of common shares available to meet the exercised options and warrants using the Black-Scholes option-pricing model.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2019
INCOME TAXES
INCOME TAXES	Note G – INCOME TAXES The Company has incurred net losses since inception, and we have determined that it is more likely than not we will be unable to benefit in the future from the accumulated net operating loss (“NOL”). Consequently, we have not recorded any U.S. federal or state income tax expense or benefit. We have not recorded income tax expense or benefit for the fiscal years ending December 31, 2019, 2018, 2017 and 2016, due to a full valuation allowance for any NOL’s that would have been generated or used. The Company has unused net operating loss carryforwards of approximately $25.9 million as of December 31, 2019 that are available to offset future income tax expense. The net operating losses will begin to expire in 2021. Based on its evaluation of tax positions, the Company has concluded that there are no significant uncertain tax positions requiring recognition in its financial statements. The Company’s evaluation was performed for all tax years, which remain subject to examination and adjustment, by major tax jurisdictions as of December 31, 2019. The Company is generally no longer subject to U.S. federal, state, and local, or non-US income tax examinations for the years before 2012.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	Note H – COMMITMENTS AND CONTINGENCIES Operating Lease The Company does not own any real property. The Company leases approximately 600 square feet of office space in Atlanta, Georgia, pursuant to a short-term lease as of August 2019. The Company currently pays base rent in the amount of $2,539 per month. The Company also leases approximately 400 square feet of office space in Berwyn, Pennsylvania, pursuant to a short-term lease as of November 2019. The Company currently pays base rent in the amount of $1,078 per month. Legal Issues The Company received notification that the United States Patent and Trademark Office (“USPTO”) had declared an Interference between Health Discovery Corporation’s pending patent application covering SVM-Recursive Feature Elimination (“SVM-RFE”) and Intel Corporation’s Patent No. 7,685,077, entitled “Recursive Feature Eliminating Method based on a Support Vector Machine”. Prior to 2013, when the America Invents Act (AIA) was enacted, a patent would be awarded to the “first to invent” a claimed invention. An Interference is an administrative proceeding within the USPTO that is used to determine which party was the first to invent an invention that is claimed in two (or more) independently owned patent applications. On February 27, 2019, the USPTO ruled in favor of the Company on the SVM-RFE Patents in the Interference proceeding between the Company and Intel Corporation. The Patent Trial and Appeal Board (“PTAB”) of the USPTO issued its decision, finding that the Company is entitled to claim exclusive rights to the SVM-RFE technology as set forth in the pending patent application that was filed to provoke the Interference. The decision, issued by Administrative Patent Judge James Moore, ordered Intel’s patent to be cancelled. The decision also dismissed Intel’s motions challenging the validity of the Company’s pending claims and issued patents covering SVM-RFE. The Company is currently evaluating its options for further action regarding this matter. The Company is subject to various claims primarily arising in the normal course of business. Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Dec. 31, 2019
CONVERTIBLE DEBT
CONVERTIBLE DEBT	Note I – CONVERTIBLE DEBT On October 23, 2017, the Company issued a convertible promissory note (the “Promissory Note”) to George H. McGovern, III, the Chairman and CEO of the Company, and James Dengler, a Company shareholder (the “Note Holders”), for $300,000 that was drawn during 2017 and 2018. The Promissory Note contained an 8% annual interest rate and the Note Holders had the right to convert the principal and unpaid accrued interest of the Promissory Note into Common Stock (“Common Stock”) of the Company at a conversion price of $0.004 On April 22, 2019, the Note Holders waived the event of default and extended the terms of the note until July 31, 2019. In consideration for the waiver and extension, the Note Holders received a 5% share of any potential recovery from the Arbitration. Such share was limited to $1 million. In connection with the announcement of the Award, the Company recorded an additional expense of $333,052, which is included in the arbitration related fees in the statement of operations for the year ended December 31, 2019. Additionally, on April 22, 2019 the Company issued a convertible promissory note (the “Additional Promissory Note”) in the amount of $200,000 to the Note Holders for funds advanced to the Company. The Additional Promissory Note was approved by the Board on August 1, 2018. Funds were advanced to the Company from August 1, 2018 through March 13, 2019. The Additional Promissory Note was executed on April 22, 2019 by the Company. The Additional Promissory Note contained an 8% annual interest rate and the Note Holders had the right to convert the principal and unpaid accrued interest of the Additional Promissory Note into Series D Preferred Stock (“Preferred Stock”) of the Company at a conversion price based upon the price of the Company’s common stock on the date of advancement of the loan amount (the “Conversion Price”). Because the loan proceeds were advanced on multiple dates, the Conversion Price varies depending upon the price of the Company’s common stock on the date of advancement of the loan amount. The right of conversion (“Optional Conversion”) is solely at the Note Holders’ discretion. On December 31, 2019, the Note Holders notified the Company of their election to convert both the Promissory Note and Additional Promissory Note into Common Stock and Series D Preferred Stock, respectively. As a result, the Note Holders received 86,927,397 shares of Common Stock on December 31, 2019 and 21,158,953 shares of Series D Preferred Stock on February 10, 2020. Additionally, on April 22, 2019, the Note Holders retain two warrants to purchase Common Stock of the Company for each share of Preferred Stock held and the price of each warrant is equal to the Conversion Price. Each warrant shall expire on July 31, 2029. These additional warrants account for 41,983,781 shares at an average weighted Conversion Price of $0.02. All of these issuances of equity securities were made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended.

STOCK COMPENSATION AND EQUITY B

STOCK COMPENSATION AND EQUITY BASED PAYMENTS	12 Months Ended
	Dec. 31, 2019
STOCK COMPENSATION AND EQUITY BASED PAYMENTS
STOCK COMPENSATION AND EQUITY BASED PAYMENTS	Note J – STOCK COMPENSATION AND EQUITY BASED PAYMENTS The following schedule summarizes combined stock option and warrant information as of December 31, 2019. Weighted Weighted Weighted Weighted Average Average Average Average Exercise Exercise Exercise Exercise Number of Warrants and Options Issued 2016 Price 2017 Price 2018 Price 2019 Price Outstanding beginning of year 46,750,000 $ 0.032 97,375,000 $ - 106,125,000 $ - - $ - Granted 54,000,000 $ 0.033 11,000,000 $ 0.003 4,000,000 $ - 8,000,000 $ 0.070 Exercised - $ - - $ - - $ - - $ - Forfeited (3,375,000) $ - (2,250,000) $ 0.050 (1,750,000) $ 0.040 - $ - Expired un-exercised - $ - - $ - - $ - - $ - Outstanding end of the year 97,375,000 106,125,000 108,375,000 8,000,000 The following table reflects stock-based compensation and expense recorded in 2019, 2018, 2017 and 2016: 2019 2018 2017 2016 Director and consultant option expenses $ 512,952 $ 83,816 $ 46,738 $ 88,418 Employee option expenses - 3,200 19,201 108,311 Total stock compensation expenses $ 512,952 $ 87,016 $ 65,939 $ 196,729 In conjunction with their appointment to the Board of Directors, the Company granted to Directors an option to purchase a total of 3,125,000 shares of the Company’s common stock in February 2016; 5,500,000 in May 2016; 11,000,000 in October 2017; 4,000,000 in May 2018 and 8,000,000 in June 2019. This activity is included in the preceding schedules within Note L summarizing stock and warrant information. In recognition of their successful efforts and continuing contributions to the Company, on June 10, 2019, the Board of Directors of the Company granted to Directors Mr. William From holzer, Ms. Colleen Hutchinson, Mr. Edward Morrison and Mr. James Murphy each a $20,000 bonus and an option to purchase 2,000,000 shares of the Company’s common stock. The options fully vested on the grant date, have an exercise price of $0.07, and expire on June 10, 2029. The fair value of each option granted is $0.0636 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.84%, an expected life of 5 years, and volatility of 149%. The aggregate computed value of these options is $508,542, and this amount was charged as an expense during the second quarter of 2019.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2019
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY	Note K - STOCKHOLDERS’ EQUITY Series B Preferred Stock The Company sold to individual investors a total of 19,402,675 shares of Series B Preferred Stock for $1,490,015, net of associated expenses, in 2009. The Series B Preferred Stock was converted into Common Stock of the Company in the fourth quarter of 2014, which was the fifth anniversary of the date of issuance as outlined in the original purchase agreement. Dividends have been accrued for the Series B Preferred Stock in the amount of $373,346 as of December 31, 2014. The Company gave the Series B holders the choice of either (1) Common Stock for the amount of the dividend accrued based upon the price of $0.05 per share or (2) to defer payment of the dividend in cash until the Company is able to pay, at the sole discretion of the Company. During the first quarter of 2015, $166,709 in dividends were paid with the issuance of 3,334,179 shares of Common Stock. The remaining accrued dividend is recorded as a current liability in the amount of $206,637 as of December 31, 2019. Series C Preferred Stock In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2014, and 2015, the Company had issued a total of 6,640,000 and 30,000,000 preferred shares, respectively. The Series C Preferred Shares were fully subscribed in the third quarter 2015. The Company received total net proceeds of $900,000, of which $568,000 was received during the year ended December 31, 2015. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were to be issued only if the Company had not attained profitability by the end of the first quarter 2016. Because the Company did not attain profitability by the end of first quarter 2016, the contingency warrants were issued. The warrant holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days. The warrants were valued at $0.022 each using the Black Scholes Method. The Series C Preferred Stock were to be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. During the first quarter of 2019, the Series C Preferred Stock was converted to common stock. Series D Preferred Stock As previously disclosed, the Company issued the Additional Promissory Note in the amount of $200,000 to the Note Holders for funds advanced to the Company. The Additional Promissory Note contained an 8% annual interest rate and the Note Holders had the right to convert the principal and unpaid accrued interest of the Additional Promissory Note into Series D Preferred Stock of the Company at the Conversion Price. The Optional Conversion is solely at the Note Holders’ discretion. On December 31, 2019, the Note Holders notified the Company of their election to convert the Additional Promissory Note into Series D Preferred Stock. As a result, the Note Holders received 20,991,891 shares of Series D Preferred Stock on February 10, 2020. Additionally, the Note Holders retain two warrants to purchase Common Stock of the Company for each share of Preferred Stock held and the price of each warrant is equal to the Conversion Price. Each warrant shall expire on July 31, 2029. Common Stock During the third quarter of 2015, the Board of Directors authorized the issuance of Common Stock in a private placement of 7,000,000 Common Shares with certain warrant features. As of December 31, 2015, 4,000,000 shares of this offering were sold, and the Company received proceeds of $120,000. The Common Shares are accompanied by $0.03 warrants and $0.06 contingency warrants. The contingency warrants were issued since the Company had not attained profitability at the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days. The warrants were valued at $0.022 each using the Black Scholes Method. On October 23, 2017, the Company issued a convertible promissory note (the “Promissory Note”) to George H. McGovern, III, the Chairman and CEO of the Company, and James Dengler, a Company shareholder (the “Note Holders”), for $300,000. The Promissory Note contained an 8% annual interest rate and the Note Holders had the right to convert the principal and unpaid accrued interest of the Promissory Note into Common Stock (“Common Stock”) of the Company at a conversion price of $0.004 Additionally, on April 22, 2019 the Company issued a convertible promissory note (the “Additional Promissory Note”) in the amount of $200,000 to the Note Holders for funds advanced to the Company. The Additional Promissory Note was approved by the Board on August 1, 2018. Funds were advanced to the Company from August 1, 2018 through March 13, 2019. The Additional Promissory Note was executed on April 22, 2019 by the Company. The Additional Promissory Note contained an 8% annual interest rate and the Note Holders had the right to convert the principal and unpaid accrued interest of the Additional Promissory Note into Series D Preferred Stock (“Preferred Stock”) of the Company at a conversion price based upon the price of the Company’s common stock on the date of advancement of the loan amount (the “Conversion Price”). Because the loan proceeds were advanced on multiple dates, the Conversion Price varies depending upon the price of the Company’s common stock on the date of advancement of the loan amount. The right of conversion (“Optional Conversion”) is solely at the Note Holders’ discretion. On December 31, 2019, the Note Holders notified the Company of their election to convert both the Promissory Note and Additional Promissory Note into Common Stock and Series D Preferred Stock, respectively. As a result, the Note Holders received 86,927,397 shares of Common Stock on December 31, 2019 and 21,158,953 shares of Series D Preferred Stock on February 10, 2020. Additionally, on April 22, 2019, the Note Holders retain two warrants to purchase Common Stock of the Company for each share of Preferred Stock held and the price of each warrant is equal to the Conversion Price. Each warrant shall expire on July 31, 2029. These additional warrants account for 41,983,781 shares at an average weighted price of $0.02. All of these issuances of equity securities were made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended. Due to the warrant features that accompany the sale of the Company’s preferred and common shares, if all outstanding options and warrants were exercised, the Company would not have sufficient shares of common stock to meet the exercised options. The aggregate intrinsic value of all options and warrants outstanding and exercisable prices. The Company will need to increase the authorized shares of common stock in order to satisfy the options and warrants if the holders exercise the outstanding options and warrants.

INVESTMENT IN AVAILABLE FOR SAL

INVESTMENT IN AVAILABLE FOR SALE SECURITIES	12 Months Ended
	Dec. 31, 2019
INVESTMENT IN AVAILABLE FOR SALE SECURITIES
INVESTMENT IN AVAILABLE FOR SALE SECURITIES	Note L – INVESTMENT IN AVAILABLE FOR SALE SECURITIES The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, as it relates to its shares held in NeoGenomics’ common stock that were acquired resulting from the NeoGenomics Master License Agreement executed on January 6, 2012. Management made the election for the fair value option related to this investment because it believes the fair value option for the NeoGenomics common stock provides a better measurement from which to compare financial statements from reporting period to reporting period. No other financial assets or liabilities are fair valued using the fair value option . As of December 31, 2017, the Company divested of all shares of NeoGenomics stock.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2019
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	Note M – SUBSEQUENT EVENTS On February 7, 2020 two shareholders of the Company, William F. Quirk, Jr. (“Quirk”) and Cindy Bear (“Bear”), filed a motion for a temporary restraining order and preliminary injunction in DeKalb County Superior Court. Among the items in the motion, Quirk and Bear requested to have a special meeting of the shareholders and Quick and Bear alleged misconduct by the Company and its directors. On March 2, 2020, having received no relief, Quirk and Bear dismissed their action in DeKalb County and filed a new lawsuit in Fulton County Superior Court based on substantially similar allegations and seeking similar relief. On March 4, 2020, the Fulton County court ordered a hearing on the emergency motion for a temporary restraining order against the Company for the following day. At the hearing on March 5, 2020, Quirk and Bear presented their version of the facts through affidavits submitted by both Quirk and Bear, arguing that the affidavits supported the emergency relief they sought. The judge denied the motion and did not enter a temporary restraining order. The court set an evidentiary hearing on Quirk and Bear’s motion for a preliminary injunction for March 27, 2020. This hearing was postponed due to the COVID‑19 pandemic and has not been rescheduled. Quirk and Bear filed this suit after attempting to call a special meeting of shareholders and making a demand for inspection of certain books and records. The Company determined the demand for a special meeting was defective for a number of reasons, but as the Company announced in December, the Company will hold an annual meeting after the Company files its annual report on Form 10‑K. The Company has provided counsel for Quirk and Bear with the records to which Quirk and Bear were legally entitled. The Company denies all allegations of improper conduct in the complaint and will continue to defend itself against all allegations. As a result, the Company will recognize expenses totaling $350,000 during the first quarter of 2020 related to legal fees associated with this litigation. Although the Company believes that it will ultimately be successful in its defense, there can be no assurance that the Company will be successful in its defense. Should Quirk and Bear be successful, the outcome could have a material adverse effect on the Company. In December 2019, a novel strain of coronavirus, COVID‑19, was reported to have surfaced in Wuhan, China. In January 2020, this coronavirus spread to other countries, including the United States, and efforts to contain the spread of COVID‑19 have intensified. The outbreak of COVID‑19 has evolved into a global pandemic. The coronavirus has spread to many regions of the world, including the areas of the United States where we operate. At this time, the United States and certain other countries are the subject of lockdowns and self-isolation procedures, which have significantly limited business operations and restricted internal and external meetings. Further, the outbreak and any preventative or protective actions that we or our customers may take in respect of COVID‑19 may result in a period of disruption to our work in progress. The extent to which the coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the coronavirus and the actions to contain the coronavirus or treat its impact, among others. Should the coronavirus continue to spread, our business operations could be delayed or interrupted. For instance, our executive officers or directors may become infected with the virus and become unable to fulfill their duties. We are taking precautionary steps to protect our executive officers consistent with White House guidance and state and local orders. The intense focus on COVID‑19 also has led to the suspension of clinical trials and research projects relating to other conditions, which may impact our ability to form new contractual arrangements to exploit our technology. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common stock. The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, or the economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely. Any resulting financial impact cannot be reasonably estimated at this time but may materially affect our business and financial condition. The extent to which COVID‑19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID‑19 and the actions to contain COVID‑19 or treat its impact, among others.

FINANCIAL CONDITION AND LIQUIDI

FINANCIAL CONDITION AND LIQUIDITY	12 Months Ended
	Dec. 31, 2019
FINANCIAL CONDITION AND LIQUIDITY
FINANCIAL CONDITION AND LIQUIDITY	Note N – FINANCIAL CONDITION AND LIQUIDITY The Company has prepared its financial statements on a “going concern” basis, which presumes that it will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. The Company’s ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing and successfully bringing the Company’s technologies to the market. The outcome of these matters cannot be predicted at this time. The Company’s financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should the Company be unable to continue in business. If the going concern assumption was not appropriate for the Company’s financial statements then adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments may be material. At December 31, 2019 the Company had $2.3 million cash on hand. As a result; the Company estimates cash will be depleted by the second quarter of 2023 if the Company does not generate sufficient cash to support operations. The Company’s plan to have sufficient cash to support operations is comprised of generating revenue through providing services related to those patents, pursuing infringement opportunities and obtaining additional equity or debt financing. The Company believes the funds received from the NeoGenomics arbitration award will allow the Company to maintain operations until second quarter 2023. While the Company believes these efforts will create a profitable future, there is no guarantee the Company will be successful in these efforts.

SELECTED QUARTERLY FINANCIAL IN

SELECTED QUARTERLY FINANCIAL INFORMATION	12 Months Ended
	Dec. 31, 2019
SELECTED QUARTERLY FINANCIAL INFORMATION
SELECTED QUARTERLY FINANCIAL INFORMATION	Note O – SELECTED QUARTERLY FINANCIAL INFORMATION The following table sets forth certain unaudited quarterly data for each of the first three quarters for the years ended December 31, 2019, and 2018, respectively. The data has been derived from the Company’s unaudited consolidated financial statements that, in management’s opinion, include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of such information when read in conjunction with the Consolidated Financial Statements and Notes thereto. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period. CONDENSED BALANCE SHEETS (UNAUDITED) As of March 31, 2018 June 30, 2018 September 30, 2018 Assets Current Assets Cash $ 96,766 $ 21,658 $ 4,539 Total Current Assets 96,766 21,658 4,539 Patents, Less Accumulated Amortization of $3.635.847, $3,701,527 and $3,767,207 as of March 31, June 30 and September 30, 2018, respectively 349,947 284,267 218,588 Total Assets $ 446,713 $ 305,925 $ 223,127 Liabilities and Stockholders’ Equity Current Liabilities Accounts Payable $ 144,823 $ 143,719 $ 151,190 Accrued Wages 191,750 236,000 280,250 Dividends Payable 206,637 206,637 206,637 Deferred Revenue 43,388 39,771 28,924 Total Current Liabilities 586,598 626,127 667,001 Long Term Liabilities Deferred Revenue 7,230 - - Convertible Debt 305,710 311,710 359,354 Total Liabilities $ 899,538 $ 937,837 $ 1,026,355 Stockholders’ Equity (Deficit) Series C Preferred Stock, Convertible, 30,000,000 Shares Authorized; 30,000,000 Issued and Outstanding March 31, June 30 and September 30, 2018 900,000 900,000 900,000 Common Stock, No Par Value, 450,000,000 Shares Authorized; 268,718,989 Shares Issued and Outstanding March 31, June 30 and September 30, 2018 28,981,241 28,993,892 29,025,231 Accumulated Deficit (30,334,066) (30,525,804) (30,728,459) Total Stockholders’ Equity (Deficit) (452,825) (631,912) (803,228) Total Liabilities and Stockholders’ Equity (Deficit) $ 446,713 $ 305,925 $ 223,127 CONDENSED BALANCE SHEETS (UNAUDITED) As of March 31, 2019 June 30, 2019 September 30, 2019 Assets Current Assets Cash $ 27,282 $ 2,681,669 $ 2,523,707 Legal fee retainer - 17,349 17,285 Total Current Assets 27,282 2,669,018 2,540,992 Patents, Less Accumulated Amortization of $3,898,566, $3,964,246 and $3,985,794 as of March 31, June 30 and September 30, 2019 87,227 21,548 - Total Assets $ 114,509 $ 2,720,566 $ 2,540,992 Liabilities and Stockholders’ Equity Current Liabilities Accounts Payable - Trade $ 148,759 $ 73,638 $ 76,193 Accrued Wages 382,138 427,738 473,338 Dividends Payable 206,637 206,637 206,637 Deferred Revenue 7,231 - - Convertible Debt 554,397 Total Current Liabilities 744,765 708,013 1,310,565 Long Term Liabilities Convertible Debt 537,064 545,731 - Total Liabilities $ 1,281,829 $ 1,253,744 $ 1,310,565 Stockholders’ Equity (Deficit) Common Stock, No Par Value, 450,000,000 Shares Authorized; 268,718,989 Shares Issued and Outstanding March 31, 2019, June 30, 2019 and September 30, 2019 29,950,534 30,460,178 30,460,178 Accumulated Deficit (31,117,854) (29,993,356) (29,229,751) Total Stockholders’ Equity (Deficit) (1,167,320) 1,466,822 1,230,427 Total Liabilities and Stockholders’ Equity (Deficit) $ 114,509 $ 2,720,566 $ 2,540,992 CONDENSED STATEMENT OF OPERATIONS (UNAUDITED) For the Quarter Ended March 31, 2018 June 30, 2018 September 30, 2018 Revenues: Licensing and Development $ 11,427 $ 10,847 $ 11,178 Total Revenue 11,427 10,847 11,178 Operating Expenses: Amortization 65,680 65,680 65,680 Professional and Consulting Fees 16,872 17,859 9,807 Legal Fees 4,249 - 6,110 Compensation 75,292 66,985 67,741 Other General and Administrative Expenses 33,401 46,061 58,352 Total Operating Expenses 195,494 196,585 207,690 (Loss) Income From Operations (184,067) (185,738) (196,512) Other Income (Expense) Interest Expense (4,500) (6,000) (6,144) Total Other Expense $ (4,500) $ (6,000) $ (6,144) Net (Loss) Income $ (188,567) $ (191,738) $ (202,656) Preferred Stock Dividends $ - $ - $ - (Loss) Income Attributable to Common Stockholders $ (188,567) $ (191,738) $ (202,656) CONDENSED STATEMENT OF OPERATIONS (UNAUDITED) For the Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 Revenues: Licensing and Development $ 10,847 $ 7,590 $ 370 Licensing Revenue from Arbitration - 1,500,000 - Total Revenue 10,847 1,507,590 370 Operating Expenses: Amortization 65,680 65,680 21,548 Professional and Consulting Fees 2,133 40,646 13,963 Legal Fees 6,474 65,013 6,597 Compensation 73,318 93,049 145,367 Other General and Administrative Expenses 30,121 628,903 40,859 Total Operating Expenses 177,726 893,291 228,334 (Loss) Income From Operations (166,879) 614,299 (227,964) Other Income (Expense) Proceeds from Arbitration - 5,161,035 - Interest Income - - 236 Arbitration related fee - (3,642,169) - Interest Expense (10,000) (8,667) (8,667) Total Other Expense $ (10,000) $ 1,510,199 $ (8,431) Net (Loss) Income $ (176,879) $ 2,124,498 $ (236,395) Preferred Stock Dividends $ - $ - $ - (Loss) Income Attributable to Common Stockholders $ (176,879) $ 2,124,498 $ (236,395)

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
USE OF ESTIMATES	USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Accordingly, actual results could differ from those estimates. Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the patent impairment.
REVENUE RECOGNITION	REVENUE RECOGNITION Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements. These arrangements are generally governed by contracts that dictate responsibilities and payment terms. The Company recognizes revenues as they are earned over the duration of a license agreement once all contractual obligations have been fulfilled. If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
CASH	CASH Cash includes cash deposited with financial institutions.
PATENTS	PATENTS Initial costs paid to purchase patents are capitalized and amortized using the straight-line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2019, the Company does not believe there has been any impairment of its patents. The Company has analyzed the respective carrying value of our patent portfolio at December 31, 2016, 2017, 2018 and 2019 and has concluded that the portfolio was not impaired during this period.
INVESTMENTS	INVESTMENTS The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies.
COMMON STOCK WARRANT LIABILITY	COMMON STOCK WARRANT LIABILITY In the event the number of shares or warrants of Common Stock granted exceeds the number of shares available if the holders exercised all of the previously issued outstanding options and warrants, the Company accounts for this excess as a Common Stock Warrant Liability, which is adjusted to fair value at the end of each reporting period. If and when the Company authorizes sufficient shares of common stock and preferred stock, the Common Stock Warrant Liability is reclassified to equity at the fair value of the liability at the date of reclassification.
INCOME TAXES	INCOME TAXES The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled. In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation is made of the probability of being able to realize the future benefits indicated by such assets. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model. Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates. Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule. Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
RESEARCH AND DEVELOPMENT EXPENSE	RESEARCH AND DEVELOPMENT EXPENSE The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. The research and development costs were $0 for 2019, 2018 and 2017 and $27,000 in 2016.
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company’s financial instruments consist of cash, available for sale securities, and accounts payable. The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note L for discussion regarding the valuation of the Company’s investment in available for sale securities.
NET INCOME (LOSS) PER SHARE	NET INCOME (LOSS) PER SHARE Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. Due to the net loss for the years ended December 31, 2018, 2017 and 2016, the calculation of diluted per share amounts would create an anti-dilutive result and therefore are not presented in the following table. Potentially dilutive shares at December 31, 2019, 2018, 2017 and 2016 include options and warrants outstanding of 116,375,000, 108,375,000, 106,125,000 and 97,375,000 respectively. The following is an analysis of the basic and diluted earnings per common share computations for the year ended December 31, 2019: Year ended December 31, 2019 Basic: Net income attributable to common stockholders $ 1,560,706 Basic weighted average common shares outstanding 388,646,386 Net income per share attributable to common stockholders - basic $ Diluted: Net income attributable to common stockholders $ 1,560,706 Basic weighted average common shares outstanding 345,742,711 Effect of dilutive securities: Conversion of options and warrants 86,927,397 Conversion of preferred shares to common shares 30,000,000 Diluted weighted average common shares outstanding 462,670,108 Net income per share attributable to common stockholders - diluted $ Please refer to Note L regarding detail for outstanding stock options.
CONCENTRATIONS OF CREDIT RISK	CONCENTRATIONS OF CREDIT RISK The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account. From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC. Management believes the risk of loss of cash balances in excess of the insured limit to be low.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of basic and diluted earnings per common share computations	Year ended December 31, 2019 Basic: Net income attributable to common stockholders $ 1,560,706 Basic weighted average common shares outstanding 388,646,386 Net income per share attributable to common stockholders - basic $ Diluted: Net income attributable to common stockholders $ 1,560,706 Basic weighted average common shares outstanding 345,742,711 Effect of dilutive securities: Conversion of options and warrants 86,927,397 Conversion of preferred shares to common shares 30,000,000 Diluted weighted average common shares outstanding 462,670,108 Net income per share attributable to common stockholders - diluted $

PATENTS (Tables)

PATENTS (Tables)	12 Months Ended
	Dec. 31, 2019
PATENTS
Schedule of cost and accumulated amortization	2019 2018 2017 2016 Cost of Patents $ 3,985,794 $ 3,985,794 $ 3,985,794 $ 3,985,794 Accumulated Amortization (3,985,794) (3,832,887) (3,570,167) (3,307,448) Patents, Net of Amortization $ - $ 152,908 $ 415,627 $ 678,346

STOCK COMPENSATION AND EQUITY_2

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
STOCK COMPENSATION AND EQUITY BASED PAYMENTS
Schedule of summarizes combined stock option and warrant	Weighted Weighted Weighted Weighted Average Average Average Average Exercise Exercise Exercise Exercise Number of Warrants and Options Issued 2016 Price 2017 Price 2018 Price 2019 Price Outstanding beginning of year 46,750,000 $ 0.032 97,375,000 $ - 106,125,000 $ - - $ - Granted 54,000,000 $ 0.033 11,000,000 $ 0.003 4,000,000 $ - 8,000,000 $ 0.070 Exercised - $ - - $ - - $ - - $ - Forfeited (3,375,000) $ - (2,250,000) $ 0.050 (1,750,000) $ 0.040 - $ - Expired un-exercised - $ - - $ - - $ - - $ - Outstanding end of the year 97,375,000 106,125,000 108,375,000 8,000,000
Schedule of stock-based compensation and expense	2019 2018 2017 2016 Director and consultant option expenses $ 512,952 $ 83,816 $ 46,738 $ 88,418 Employee option expenses - 3,200 19,201 108,311 Total stock compensation expenses $ 512,952 $ 87,016 $ 65,939 $ 196,729

SELECTED QUARTERLY FINANCIAL _2

SELECTED QUARTERLY FINANCIAL INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2019
SELECTED QUARTERLY FINANCIAL INFORMATION
Schedule of quarterly financial information	CONDENSED BALANCE SHEETS (UNAUDITED) As of March 31, 2018 June 30, 2018 September 30, 2018 Assets Current Assets Cash $ 96,766 $ 21,658 $ 4,539 Total Current Assets 96,766 21,658 4,539 Patents, Less Accumulated Amortization of $3.635.847, $3,701,527 and $3,767,207 as of March 31, June 30 and September 30, 2018, respectively 349,947 284,267 218,588 Total Assets $ 446,713 $ 305,925 $ 223,127 Liabilities and Stockholders’ Equity Current Liabilities Accounts Payable $ 144,823 $ 143,719 $ 151,190 Accrued Wages 191,750 236,000 280,250 Dividends Payable 206,637 206,637 206,637 Deferred Revenue 43,388 39,771 28,924 Total Current Liabilities 586,598 626,127 667,001 Long Term Liabilities Deferred Revenue 7,230 - - Convertible Debt 305,710 311,710 359,354 Total Liabilities $ 899,538 $ 937,837 $ 1,026,355 Stockholders’ Equity (Deficit) Series C Preferred Stock, Convertible, 30,000,000 Shares Authorized; 30,000,000 Issued and Outstanding March 31, June 30 and September 30, 2018 900,000 900,000 900,000 Common Stock, No Par Value, 450,000,000 Shares Authorized; 268,718,989 Shares Issued and Outstanding March 31, June 30 and September 30, 2018 28,981,241 28,993,892 29,025,231 Accumulated Deficit (30,334,066) (30,525,804) (30,728,459) Total Stockholders’ Equity (Deficit) (452,825) (631,912) (803,228) Total Liabilities and Stockholders’ Equity (Deficit) $ 446,713 $ 305,925 $ 223,127 CONDENSED BALANCE SHEETS (UNAUDITED) As of March 31, 2019 June 30, 2019 September 30, 2019 Assets Current Assets Cash $ 27,282 $ 2,681,669 $ 2,523,707 Legal fee retainer - 17,349 17,285 Total Current Assets 27,282 2,669,018 2,540,992 Patents, Less Accumulated Amortization of $3,898,566, $3,964,246 and $3,985,794 as of March 31, June 30 and September 30, 2019 87,227 21,548 - Total Assets $ 114,509 $ 2,720,566 $ 2,540,992 Liabilities and Stockholders’ Equity Current Liabilities Accounts Payable - Trade $ 148,759 $ 73,638 $ 76,193 Accrued Wages 382,138 427,738 473,338 Dividends Payable 206,637 206,637 206,637 Deferred Revenue 7,231 - - Convertible Debt 554,397 Total Current Liabilities 744,765 708,013 1,310,565 Long Term Liabilities Convertible Debt 537,064 545,731 - Total Liabilities $ 1,281,829 $ 1,253,744 $ 1,310,565 Stockholders’ Equity (Deficit) Common Stock, No Par Value, 450,000,000 Shares Authorized; 268,718,989 Shares Issued and Outstanding March 31, 2019, June 30, 2019 and September 30, 2019 29,950,534 30,460,178 30,460,178 Accumulated Deficit (31,117,854) (29,993,356) (29,229,751) Total Stockholders’ Equity (Deficit) (1,167,320) 1,466,822 1,230,427 Total Liabilities and Stockholders’ Equity (Deficit) $ 114,509 $ 2,720,566 $ 2,540,992 CONDENSED STATEMENT OF OPERATIONS (UNAUDITED) For the Quarter Ended March 31, 2018 June 30, 2018 September 30, 2018 Revenues: Licensing and Development $ 11,427 $ 10,847 $ 11,178 Total Revenue 11,427 10,847 11,178 Operating Expenses: Amortization 65,680 65,680 65,680 Professional and Consulting Fees 16,872 17,859 9,807 Legal Fees 4,249 - 6,110 Compensation 75,292 66,985 67,741 Other General and Administrative Expenses 33,401 46,061 58,352 Total Operating Expenses 195,494 196,585 207,690 (Loss) Income From Operations (184,067) (185,738) (196,512) Other Income (Expense) Interest Expense (4,500) (6,000) (6,144) Total Other Expense $ (4,500) $ (6,000) $ (6,144) Net (Loss) Income $ (188,567) $ (191,738) $ (202,656) Preferred Stock Dividends $ - $ - $ - (Loss) Income Attributable to Common Stockholders $ (188,567) $ (191,738) $ (202,656) CONDENSED STATEMENT OF OPERATIONS (UNAUDITED) For the Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 Revenues: Licensing and Development $ 10,847 $ 7,590 $ 370 Licensing Revenue from Arbitration - 1,500,000 - Total Revenue 10,847 1,507,590 370 Operating Expenses: Amortization 65,680 65,680 21,548 Professional and Consulting Fees 2,133 40,646 13,963 Legal Fees 6,474 65,013 6,597 Compensation 73,318 93,049 145,367 Other General and Administrative Expenses 30,121 628,903 40,859 Total Operating Expenses 177,726 893,291 228,334 (Loss) Income From Operations (166,879) 614,299 (227,964) Other Income (Expense) Proceeds from Arbitration - 5,161,035 - Interest Income - - 236 Arbitration related fee - (3,642,169) - Interest Expense (10,000) (8,667) (8,667) Total Other Expense $ (10,000) $ 1,510,199 $ (8,431) Net (Loss) Income $ (176,879) $ 2,124,498 $ (236,395) Preferred Stock Dividends $ - $ - $ - (Loss) Income Attributable to Common Stockholders $ (176,879) $ 2,124,498 $ (236,395)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2019USD ($)patent	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of patents issued | patent	31
Useful life	17 years
Research and development costs	$ 0	$ 0	$ 0	$ 27,000
Cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation per account	$ 250,000

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended						12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Dilutive shares							116,375,000	108,375,000	106,125,000	97,375,000
Basic:
Net income attributable to common stockholders	$ (236,395)	$ 2,124,498	$ (176,879)	$ (202,656)	$ (191,738)	$ (188,567)	$ 1,560,706	$ (795,474)	$ (873,887)	$ (2,068,619)
Basic weighted average common shares outstanding							388,646,386	271,718,989	271,718,989	271,718,989
Net income per share attributable to common stockholders - basic							$ 0	$ 0	$ 0	$ 0
Diluted:
Net Income (Loss) Available to Common Stockholders, Diluted							$ 1,560,706
Basic weighted average common shares outstanding							345,742,711
Effect of dilutive securities:
Conversion of options and warrants							86,927,397
Conversion of preferred shares to common shares							30,000,000
Diluted weighted average common shares outstanding							462,670,108
Net income per share attributable to common stockholders - diluted							$ 0

ARBITRATION (Details)

ARBITRATION (Details) - USD ($)	Apr. 25, 2019	Dec. 31, 2019
Gain Contingencies [Line Items]
Awarded Amount		$ 6,608,694
Proceeds from the arbitration were recognized as revenue		6,600,000
Punitive damages		5,100,000
Litigation expenses		3,642,170
NeoGenomics Case
Gain Contingencies [Line Items]
Awarded Amount	$ 5,100,000
Reimburse amount	8,694
Proceeds from the arbitration were recognized as revenue		$ 1,500,000
SmartFlow infringes Case
Gain Contingencies [Line Items]
Awarded Amount	$ 1,500,000

DEFERRED REVENUE (Details)

DEFERRED REVENUE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred revenue	$ 0	$ 18,077	$ 61,465	$ 104,853
Minimum [Member]
Finite-Lived Intangible Assets, Remaining Amortization Period	1 year
Maximum
Finite-Lived Intangible Assets, Remaining Amortization Period	7 years

PATENTS (Details)

PATENTS (Details) - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (3,985,794)	$ (3,985,794)	$ (3,964,246)	$ (3,898,566)	$ (3,832,887)	$ (3,767,207)	$ (3,701,527)		$ (3,570,167)	$ (3,307,448)
Patents, Net of Amortization			$ 21,548	$ 87,227	152,908	$ 218,588	$ 284,267	$ 349,947	415,627	678,346
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost of Patents	3,985,794				3,985,794				3,985,794	3,985,794
Accumulated Amortization	$ (3,985,794)				(3,832,887)				(3,570,167)	(3,307,448)
Patents, Net of Amortization					$ 152,908				$ 415,627	$ 678,346

INVESTMENTS (Details)

INVESTMENTS (Details) - S V M Capital, L L C [Member] - USD ($)	Mar. 27, 2007	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Percentage of ownership	45.00%
Amount invested	$ 5,000
Carrying value of investment		$ 0	$ 0	$ 0	$ 0

COMMON STOCK WARRANTS LIABILI_2

COMMON STOCK WARRANTS LIABILITY (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2019	Dec. 31, 2016	Apr. 22, 2019
Class of Warrant or Right [Line Items]
Warrants to purchase common stock				41,983,781
Reclassified the liability to stockholders' equity			$ 1,535,880
Number of shares for common stock converted		86,927,397
Reclassification of Common Stock Warrants		$ 1,898,126
Preferred Stock
Class of Warrant or Right [Line Items]
Reclassified the liability to stockholders' equity			$ 339,268
Preferred Stock | Private Placement
Class of Warrant or Right [Line Items]
Shares issued	30,000,000
Common Stock
Class of Warrant or Right [Line Items]
Shares issued			3,000,000
Reclassified the liability to stockholders' equity		$ 1,196,612,000	$ 1,196,612
Number of shares for common stock converted		86,927,397
Reclassification of Common Stock Warrants		$ 1,898,126
Common Stock | Private Placement
Class of Warrant or Right [Line Items]
Shares issued	4,000,000
Warrants to purchase common stock	34,000,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
INCOME TAXES
Income tax expense	$ 0	$ 0	$ 0	$ 0
Net operating loss carry-forwards	$ 25,900,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	1 Months Ended
	Nov. 30, 2019USD ($)ft²	Aug. 31, 2019USD ($)ft²
Office Space in Atlanta
Lessee, Lease, Description [Line Items]
Area of land | ft²		600
Monthly rental expenses | $		$ 2,539
Office Space in Berwyn
Lessee, Lease, Description [Line Items]
Area of land | ft²	400
Monthly rental expenses | $	$ 1,078

CONVERTIBLE DEBT (Details)

CONVERTIBLE DEBT (Details)	Feb. 10, 2020item	Apr. 22, 2019USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)item	Oct. 23, 2017$ / shares
Debt Instrument [Line Items]
Arbitration related fee			$ 3,642,169	$ 3,642,170
Warrants to purchase shares | shares		41,983,781
Conversion price | $ / shares		$ 0.02
Convertible promissory note
Debt Instrument [Line Items]
Amount of debt		$ 200,000		$ 300,000
Interest rate		8.00%			8.00%
Conversion price per share | $ / shares					$ 0.004
Percentage of share received		5.00%
Arbitration related fee		$ 333,052
Convertible promissory note | Maximum
Debt Instrument [Line Items]
Amount received by note holders		$ 1,000,000
Convertible promissory note | Common Stock
Debt Instrument [Line Items]
Number of shares issued | item				86,927,397
Convertible promissory note | Series D Preferred Stock
Debt Instrument [Line Items]
Amount of debt				$ 200,000
Interest rate				8.00%
Number of shares issued | item	21,158,953

STOCK COMPENSATION AND EQUITY_3

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details) - $ / shares	Jun. 10, 2019	Jun. 30, 2019	May 31, 2018	Oct. 31, 2017	May 31, 2016	Feb. 29, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Warrants and Options Issued
Granted	2,000,000	8,000,000	4,000,000	11,000,000	5,500,000	3,125,000
Weighted Average Exercise Price
Granted	$ 0.07
Stock Option and Warrants
Number of Warrants and Options Issued
Outstanding beginning of year							108,375,000	106,125,000	97,375,000	46,750,000
Granted							8,000,000	4,000,000	11,000,000	54,000,000
Exercised								(1,750,000)	(2,250,000)	(3,375,000)
Outstanding end of the year							8,000,000	108,375,000	106,125,000	97,375,000
Weighted Average Exercise Price
Outstanding beginning of year										$ 0.032
Granted							$ 0.070		$ 0.003	$ 0.033
Exercised								$ 0.040	$ 0.050

STOCK COMPENSATION AND EQUITY_4

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details 1) - USD ($)	Jun. 10, 2019	Jun. 30, 2019	May 31, 2018	Oct. 31, 2017	May 31, 2016	Feb. 29, 2016	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock compensation expenses							$ 508,542	$ 512,952	$ 87,016	$ 65,939	$ 196,729
Option granted to purchase of common stock	2,000,000	8,000,000	4,000,000	11,000,000	5,500,000	3,125,000
Exercise price of options fully vested on the grant date	$ 0.07
fair value of option granted	$ 0.0636
Fair value assumptions
Dividend yield	0.00%
Risk-free interest rate	1.84%
Expected life	5 years
Volatility	149.00%
Compensation expenses							$ 508,542	512,952	87,016	65,939	196,729
Director and consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock compensation expenses								512,952	83,816	46,738	88,418
Fair value assumptions
Compensation expenses								$ 512,952	83,816	46,738	88,418
Employee option expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock compensation expenses									3,200	19,201	108,311
Fair value assumptions
Compensation expenses									$ 3,200	$ 19,201	$ 108,311
William Fromholzer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus	$ 20,000
Ms. Colleen Hutchinson
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus	20,000
Mr. Edward Morrison
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus	20,000
Mr. James Murphy
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus	$ 20,000

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($)

Feb. 10, 2020

Sep. 30, 2015

Mar. 31, 2015

Dec. 31, 2013

Dec. 31, 2019

Dec. 31, 2015

Dec. 31, 2009

Sep. 30, 2019

Jun. 30, 2019

Apr. 22, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Oct. 23, 2017

Dec. 31, 2016

Dec. 31, 2014

Class of Stock [Line Items]

Dividend current liability

$ 206,637

$ 206,637

$ 206,637

$ 206,637

$ 206,637

$ 206,637

$ 206,637

$ 206,637

$ 206,637

$ 206,637

Preferred stock, shares issued

30,000,000

30,000,000

30,000,000

Warrant

Class of Stock [Line Items]

Stock value per share

$ 0.03

Warrants and Rights Outstanding

$ 0.022

Warrant | Market Price of Common Stock is 0.20

Class of Stock [Line Items]

Stock value per share

$ 0.20

Percentage of warrants exercise

50.00%

Warrant | Market Price of Common Stock is 0.30

Class of Stock [Line Items]

Stock value per share

$ 0.30

Percentage of warrants exercise

50.00%

Contingent Warrant

Class of Stock [Line Items]

Stock value per share

$ 0.06

Convertible promissory note

Class of Stock [Line Items]

Amount of debt

300,000

$ 200,000

Interest rate

8.00%

8.00%

Series B Preferred Stock

Class of Stock [Line Items]

Number of shares sold

19,402,675

Consideration for sale of stock, net of associated expenses

$ 1,490,015

Dividends accrued

$ 373,346

Share price per share

$ 0.05

Amount of dividend paid in stock

$ 166,709

Number of stock issued for dividends

3,334,179

Dividend current liability

206,637

Series C Preferred Stock

Class of Stock [Line Items]

Preferred stock, shares issued

30,000,000

6,640,000

Net cash proceeds

900,000

$ 568,000

Series C Preferred Stock | Warrant

Class of Stock [Line Items]

Stock value per share

$ 0.03

Warrants and Rights Outstanding

$ 0.022

Series C Preferred Stock | Warrant | Market Price of Common Stock is 0.20

Class of Stock [Line Items]

Stock value per share

$ 0.20

Percentage of warrants exercise

50.00%

Series C Preferred Stock | Warrant | Market Price of Common Stock is 0.30

Class of Stock [Line Items]

Stock value per share

$ 0.30

Percentage of warrants exercise

50.00%

Series C Preferred Stock | Contingent Warrant

Class of Stock [Line Items]

Stock value per share

$ 0.03

Series D Preferred Stock | Convertible promissory note

Class of Stock [Line Items]

Amount of debt

$ 200,000

Interest rate

8.00%

Amount of note holders received

20,991,891

STOCKHOLDERS' EQUITY - Common S

STOCKHOLDERS' EQUITY - Common Stock (Details)	Feb. 10, 2020item	Sep. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2019USD ($)item	Dec. 31, 2015USD ($)shares	Apr. 22, 2019USD ($)$ / sharesshares	Oct. 27, 2017USD ($)$ / shares	Oct. 23, 2017$ / shares
Class of Stock [Line Items]
Warrants to purchase shares | shares					41,983,781
Conversion price					$ 0.02
Convertible promissory note
Class of Stock [Line Items]
Amount of debt | $			$ 300,000		$ 200,000
Interest rate					8.00%		8.00%
Conversion price per share							$ 0.004
Series D Preferred Stock | Convertible promissory note
Class of Stock [Line Items]
Amount of debt | $			$ 200,000
Interest rate			8.00%
Number of shares issued | item	21,158,953
Common Stock
Class of Stock [Line Items]
Number of shares issued | shares				4,000,000
Consideration for sale of stock, net of associated expenses | $				$ 120,000
Common Stock | Convertible promissory note
Class of Stock [Line Items]
Amount of debt | $					$ 200,000	$ 300,000
Interest rate					8.00%	8.00%
Conversion price per share						$ 0.004
Number of shares issued | item			86,927,397
Warrant
Class of Stock [Line Items]
Stock value per share		$ 0.03
Warrants | $		$ 0.022
Warrant | Market Price of Common Stock is 0.20
Class of Stock [Line Items]
Stock value per share		$ 0.20
Percentage of warrants exercise		50.00%
Warrant | Market Price of Common Stock is 0.30
Class of Stock [Line Items]
Stock value per share		$ 0.30
Percentage of warrants exercise		50.00%
Private Placement | Common Stock
Class of Stock [Line Items]
Number of shares authorized to issue | shares		7,000,000
Warrants to purchase shares | shares		34,000,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	Feb. 07, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Subsequent Event [Line Items]
Litigation expenses			$ 3,642,170
Subsequent Event
Subsequent Event [Line Items]
Number of shareholders filed temporary restraining order	2
Litigation expenses		$ 350,000

FINANCIAL CONDITION AND LIQUI_2

FINANCIAL CONDITION AND LIQUIDITY (Details) - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
FINANCIAL CONDITION AND LIQUIDITY
Cash on hand	$ 2,295,720	$ 2,523,707	$ 2,681,669	$ 27,282	$ 67	$ 4,539	$ 21,658	$ 96,766	$ 43,543	$ 41,251

SELECTED QUARTERLY FINANCIAL _3

SELECTED QUARTERLY FINANCIAL INFORMATION - CONDENSED BALANCE SHEETS (Details) - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash	$ 2,295,720	$ 2,523,707	$ 2,681,669	$ 27,282	$ 67	$ 4,539	$ 21,658	$ 96,766	$ 43,543	$ 41,251
Legal fee retainer	16,796	17,285	17,349
Total Current Assets	2,312,516	2,540,992	2,669,018	27,282	67	4,539	21,658	96,766	43,543	195,625
Patents, Less Accumulated Amortization			21,548	87,227	152,908	218,588	284,267	349,947	415,627	678,346
Total Assets	2,312,516	2,540,992	2,720,566	114,509	152,975	223,127	305,925	446,713	459,170	873,971
Current Liabilities
Accounts Payable - Trade	21,483	76,193	73,638	148,759	148,208	151,190	143,719	144,823	152,648	39,823
Accrued Wages	440,089	473,338	427,738	382,138	339,677	280,250	236,000	191,750	147,500
Dividends Payable	206,637	206,637	206,637	206,637	206,637	206,637	206,637	206,637	206,637	206,637
Deferred Revenue				7,231	18,077	28,924	39,771	43,388	43,388	43,388
Convertible Debt	200,000	554,397			407,060
Total Current Liabilities	2,783,023	1,310,565	708,013	744,765	1,146,723	667,001	626,127	586,598	551,383	289,848
Long Term Liabilities
Deferred Revenue								7,230	18,077	61,465
Convertible Debt			545,731	537,064		359,354	311,710	305,710	175,000
Total Liabilities	2,783,023	1,310,565	1,253,744	1,281,829	1,146,723	1,026,355	937,837	899,538	744,460	351,313
Stockholders' Equity (Deficit)
Preferred Stock					900,000	900,000	900,000	900,000	900,000	900,000
Common Stock	28,909,761				29,047,226	29,025,231	28,993,892	28,981,241	28,960,210	28,894,271
Accumulated Deficit	(29,380,268)	(29,229,751)	(29,993,356)	(31,117,854)	(30,940,974)	(30,728,459)	(30,525,804)	(30,334,066)	(30,145,500)	(29,271,613)
Total Stockholders' Equity (Deficit)	(470,507)	1,230,427	1,466,822	(1,167,320)	(993,748)	(803,228)	(631,912)	(452,825)	(285,290)	522,658	$ 768,668
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,312,516	$ 2,540,992	$ 2,720,566	$ 114,509	$ 152,975	$ 223,127	$ 305,925	$ 446,713	$ 459,170	$ 873,971

SELECTED QUARTERLY FINANCIAL _4

SELECTED QUARTERLY FINANCIAL INFORMATION - CONDENSED BALANCE SHEETS (Parenthetical) (Details) - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
SELECTED QUARTERLY FINANCIAL INFORMATION
Patents, accumulated amortization	$ 3,985,794	$ 3,985,794	$ 3,964,246	$ 3,898,566	$ 3,832,887	$ 3,767,207	$ 3,701,527		$ 3,570,167	$ 3,307,448
Preferred stock, shares authorized						30,000,000	30,000,000	30,000,000
Preferred stock, shares issued						30,000,000	30,000,000	30,000,000
Preferred stock, shares outstanding	0					30,000,000	30,000,000	30,000,000
Common stock, par value (in dollars per share)	$ 0	$ 0	$ 0	$ 0		$ 0	$ 0	$ 0
Common stock, shares authorized	450,000,000	450,000,000	450,000,000	450,000,000	450,000,000	450,000,000	450,000,000	450,000,000	450,000,000	450,000,000
Common stock, shares issued		268,718,989	268,718,989	268,718,989	388,648,386	268,718,989	268,718,989	268,718,989
Common stock, shares outstanding			268,718,989	268,718,989	268,718,989	268,718,989	268,718,989	268,718,989	268,718,989	268,718,989

SELECTED QUARTERLY FINANCIAL _5

SELECTED QUARTERLY FINANCIAL INFORMATION - CONDENSED STATEMENT OF OPERATIONS (Details) - USD ($)	3 Months Ended						12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total Revenue	$ 370	$ 1,507,590	$ 10,847	$ 11,178	$ 10,847	$ 11,427	$ 1,518,806	$ 44,300	$ 44,951	$ 43,512
Depreciation and Amortization	21,548	65,680	65,680	65,680	65,680	65,680	152,908	262,719	262,719	262,914
Professional and Consulting Fees	13,963	40,646	2,133	9,807	17,859	16,872	83,735	59,456	126,799	213,977
Legal Fees	6,597	65,013	6,474	6,110		4,249	86,997	10,359	72,020	32,458
Compensation	145,367	93,049	73,318	67,741	66,985	75,292	371,690	285,421	308,631	282,195
Other General and Administrative Expenses	40,859	628,903	30,121	58,352	46,061	33,401	745,023	195,965	134,382	179,093
Total Operating Expenses	228,334	893,291	177,726	207,690	196,585	195,494	1,440,353	813,920	904,551	997,657
Income (Loss) From Operations	(227,964)	614,299	(166,879)	(196,512)	(185,738)	(184,067)	78,453	(769,620)	(859,600)	(954,145)
Proceeds from Arbitration		5,161,035					5,161,035
Interest Income	236						721
Arbitration related fee		(3,642,169)					(3,642,170)
Interest Expense	(8,667)	(8,667)	(10,000)	(6,144)	(6,000)	(4,500)	(37,333)	(25,854)	(1,210)
Total Other Income (Expense)	(8,431)	1,510,199	(10,000)	(6,144)	(6,000)	(4,500)	1,482,253	(25,854)	(14,287)	(1,114,474)
Net Income (Loss)	(236,395)	2,124,498	(176,879)	(202,656)	(191,738)	(188,567)	1,560,706	(795,474)	(873,887)	(2,068,619)
Income (Loss) Attributable to Common Stockholders	(236,395)	2,124,498	(176,879)	(202,656)	(191,738)	(188,567)	1,560,706	(795,474)	(873,887)	(2,068,619)
Licensing and Development
Total Revenue	$ 370	7,590	$ 10,847	$ 11,178	$ 10,847	$ 11,427	18,806	$ 44,300	$ 44,951	$ 43,512
Licensing Revenue from Arbitration
Total Revenue		$ 1,500,000					$ 1,500,000